Biotech startups extend runway by planning cash around scientific milestones, not calendar months. That means building a milestone-based budget, forecasting burn under several scenarios, managing contract research spend closely, layering in non-dilutive funding such as grants and R&D tax credits, and starting the next raise well before cash gets tight. fractional CFO for biotech companies
In most industries, running low on cash is a problem. In biotech, it can end a program that took years to build. A promising compound, a platform technology, or a diagnostic can lose its momentum simply because the money ran out a few months before the data that would have unlocked the next round. Timelines slip, experiments fail, and regulatory steps take longer than planned, yet the burn continues every month.
That reality is why many life science founders bring in a fractional CFO for biotech companies long before they could justify a full-time finance executive. The goal is simple but demanding: make every dollar of investor capital carry the company as far as possible toward value-creating milestones.
This guide covers the cash planning practices that give biotech startups the most room to operate between funding rounds.
Why Biotech Cash Planning Is Different
A software company can often cut spending, change pricing, or find revenue quickly. Most early-stage biotech companies cannot. They typically have little or no revenue, long development cycles, and costs that are hard to pause without damaging the science.
Several factors make biotech cash planning uniquely challenging:
- Binary outcomes: A study result can dramatically change the company’s valuation, direction, or funding options.
- Lumpy spending: Large payments for contract research, manufacturing runs, or clinical activities arrive in bursts rather than evenly.
- Long lead times: Ordering materials, securing lab space, or booking a contract research organization (CRO) can take months.
- Investor expectations tied to data: The next round usually depends on hitting a specific scientific or regulatory milestone.
- Specialized talent: Scientific staff are expensive and hard to replace, so headcount cuts carry real risk.
Because of these pressures, a standard annual budget is rarely enough. Biotech companies need a plan that connects spending directly to the milestones that will drive the next financing.
Build the Budget Around Milestones
Definition: A milestone-based budget organizes spending by the scientific, clinical, or regulatory achievements the company is working toward, such as completing IND-enabling studies, generating proof-of-concept data, or finishing a first-in-human trial, rather than by department alone.
This approach answers the question investors care about most: how much money does it take to reach the next inflection point?
To build one:
- List the milestones that will support the next raise. Be specific about what data or approvals are needed.
- Map every activity required to reach each milestone, including studies, materials, manufacturing, regulatory work, and staffing.
- Estimate costs and timing for each activity, with input from scientific leadership and vendors.
- Add a realistic buffer. Experiments often need repeating, and timelines rarely run shorter than planned.
- Identify which spending is essential and which can wait. This becomes your playbook if cash gets tight.
A milestone budget also makes board conversations easier. Instead of debating individual line items, leadership can discuss whether the company is on track to hit the data that matters.
Forecast Burn Under More Than One Scenario
A single forecast gives a false sense of certainty. Biotech companies benefit from modeling several versions of the future.
Base Case
Milestones are achieved on the current timeline and within the planned budget.
How it is used: Day-to-day planning and investor updates.
Delay Case
Key studies take three to six months longer than planned.
How it is used: Tests whether runway survives common setbacks.
Lean Case
Non-essential programs are paused and hiring is frozen.
How it is used: Shows how far cash can stretch if necessary.
Upside Case
Early data, a partnership, or a grant arrives sooner than expected.
How it is used: Guides decisions on accelerating programs.
Each scenario should show monthly cash balance, burn rate, and the date cash falls below a minimum safety level. Reviewing these monthly allows leadership to spot trouble early and adjust before options disappear.
Companies that work with experienced cash flow management consulting partners often use rolling forecasts that update every month with actual results, so the runway estimate always reflects reality rather than assumptions made at the last raise.
Control the Largest Cost Drivers
In many biotech startups, a handful of categories make up most of the burn. Small improvements in these areas can add months of runway.
Contract Research and Manufacturing
CROs and contract manufacturers often represent a major share of spending. Review contracts carefully for payment schedules, change-order terms, and cancellation provisions. Tie payments to deliverables where possible, and track work performed against amounts paid so the company does not prepay far ahead of progress.
Headcount
Salaries and benefits add up quickly. Consider whether some specialized work can be handled by consultants or contract scientists until a program proves out.
Lab Space and Equipment
Shared lab facilities, incubators, and equipment leasing can reduce large upfront commitments. Buying expensive equipment too early ties up cash that may be needed for experiments.
Materials and Supplies
Reagents, cell lines, and specialty materials can carry long lead times and high costs. Better purchasing coordination helps avoid rush fees and waste.
Accruals
Because research work often happens before invoices arrive, accurate accruals are essential. Without them, financial statements can understate spending, and the company may believe it has more runway than it actually does.
Layer In Non-Dilutive Funding
Every dollar that does not come from selling equity helps reduce the amount of capital that needs to be raised through equity financing. Biotech companies have several options worth exploring.
Government Grants
Programs such as Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards, along with NIH and other agency grants, can fund specific research programs. Grants often come with detailed compliance and reporting requirements, so strong accounting controls matter.
R&D Tax Credits
Research into new compounds, therapies, diagnostics, and platform technologies may qualify for the federal research credit. Working with an R&D tax credit consulting partner can help identify qualifying wages, supplies, and contract research costs.
Qualified small businesses that are not yet profitable may be able to apply the credit against payroll taxes, turning it into near-term cash. Research funded by grants or other parties may be treated differently when calculating the credit, so the two should be planned together.
Strategic Partnerships
Licensing deals, research collaborations, and co-development agreements can bring upfront payments and milestone fees while validating the science.
Venture Debt
For companies with strong investor backing, venture debt can extend runway between equity rounds. It carries repayment obligations and covenants, so it should be modeled carefully before signing.
Protect the Cash You Already Have
Runway is not only about spending less. It is also about managing the money on hand wisely.
- Keep a clear minimum cash threshold that triggers action, such as starting a raise or activating the lean plan.
- Spread deposits thoughtfully and review bank relationships and deposit coverage, since concentration can create risk.
- Invest idle cash conservatively in liquid, low-risk options aligned with the company’s investment policy.
- Set approval limits for spending so large commitments receive proper review.
- Report cash position to the board regularly with a consistent format that shows actual results against the plan.
Start the Next Raise Before You Need It
One of the common mistakes in biotech is waiting too long to raise. Fundraising can take months, and investors may become more cautious when a company is visibly close to running out of cash.
A practical approach is to begin preparing well before the company reaches its minimum runway threshold, ideally while there is still enough cash to reach the next milestone even if the round takes longer than expected.
Preparation includes:
- Updating the financial model
- Organizing the data room
- Cleaning up accruals and cap table records
- Preparing a clear use-of-funds plan
- Connecting fundraising needs to upcoming scientific milestones
- Reviewing potential grants and other non-dilutive funding
Inside K-38 Consulting’s Approach to Biotech Finance
K-38 Consulting, a Raleigh, North Carolina-based finance firm founded by Dallas Alford IV, CPA, provides dedicated CFO support for biotech startups alongside its work with startups and midsize businesses across the United States.
The firm’s model pairs each client with a finance team that typically includes both a controller and a CFO. The controller manages accurate books, research accruals, and a dependable monthly close, while the CFO focuses on runway planning, milestone budgeting, scenario forecasting, grant and funding management, and fundraising strategy.
For biotech founders, this approach allows scientific leadership to stay focused on research while the finance team keeps the cash plan aligned with scientific and business milestones.
Because K-38 Consulting also offers R&D tax credit services, biotech clients can connect potential non-dilutive funding directly to their runway plans rather than treating tax credits as an afterthought.
The team works with established platforms such as QuickBooks and NetSuite and uses web-based forecasting tools that provide leadership with a current view of burn and cash position.
According to the firm, many businesses lose significant time each month to manual accounting work, so automation is part of how it sets up client finance operations.
Client results also reflect this focus. Dover Therapeutics, a biotech startup, has credited K-38 Consulting with helping optimize financial operations, improve cash flow, strengthen business processes, and provide strategic insight and forecasting tools supporting funding and growth decisions.
K-38 Consulting serves clients in markets including Raleigh, Charlotte, Atlanta, Tampa, Miami, Austin, New York City, Chicago, San Francisco, San Jose, and Los Angeles.
Biotech founders can book a strategy session with the firm to review runway, funding plans, and financial readiness for the next round.
Runway Stress Test: Eight Questions for Your Leadership Team
Work through these questions with your leadership team and board:
- Do we know exactly how much cash is needed to reach the next value-creating milestone?
- Does our forecast include a delay scenario, and does runway survive it?
- Are research accruals recorded accurately each month?
- Are CRO and manufacturing payments tied to deliverables?
- Have we reviewed eligibility for the R&D tax credit and potential payroll tax offset?
- Are we pursuing grants or partnerships that fit our programs?
- Do we have a defined minimum cash threshold and a lean-case plan?
- When do we need to start fundraising to close before reaching that threshold?
If any answer is uncertain, that is the place to focus next.
Biotech Runway Questions, AnsweredHow much runway should a biotech startup keep after a raise?
Many companies aim to raise enough capital to reach the next major milestone with additional buffer for delays. The appropriate amount depends on the program, development stage, expected costs, and fundraising environment. Planning for setbacks is essential.
Can a pre-revenue biotech company claim the R&D tax credit?
Potentially. Qualified small businesses may be able to apply the credit against certain payroll taxes even without income tax liability. Eligibility and the applicable rules should be reviewed with a qualified tax advisor.
Why are research accruals so important?
Research work is often performed before invoices arrive. Without accurate accruals, financial statements can understate spending, causing runway to appear longer than it really is.
When should a biotech startup bring in a CFO?
Many companies can benefit from part-time or outsourced CFO support early, particularly before a priced funding round, a major grant application, or the start of expensive preclinical or clinical work.
What is a milestone-based budget?
A milestone-based budget organizes financial resources around specific scientific, clinical, or regulatory objectives. It helps management understand how much capital is required to reach each important development milestone.
What is a runway stress test?
A runway stress test examines how long the company’s available cash would last under different circumstances, such as delayed studies, unexpected costs, slower fundraising, or reduced spending.
How can a biotech startup reduce its monthly burn?
Companies can review CRO contracts, control hiring, delay non-essential programs, optimize purchasing, use shared laboratory facilities, and improve financial forecasting. The objective is to reduce unnecessary spending without compromising critical scientific milestones.
What is non-dilutive funding?
Non-dilutive funding provides capital without requiring the company to give up additional equity. Examples can include grants, certain tax credits, research collaborations, and licensing-related payments.
Should biotech startups consider venture debt?
Venture debt can provide additional capital without an immediate equity issuance, but it introduces repayment obligations, interest costs, and potentially restrictive covenants. Companies should model the financial consequences carefully before taking on debt.
Why should biotech companies use multiple cash-flow scenarios?
Biotech development is subject to scientific, regulatory, operational, and timing uncertainty. Multiple scenarios help leadership understand how different outcomes could affect cash requirements and runway.
How often should a biotech startup update its cash forecast?
A rolling forecast is generally more useful than relying on an annual budget alone. Updating the forecast regularly with actual spending, new commitments, revised timelines, and current cash balances helps management identify changes in runway earlier.
What expenses should biotech startups monitor most closely?
Common major cost categories include CRO services, contract manufacturing, scientific payroll, laboratory space, equipment, research materials, regulatory activities, and other development-related expenses.
How can grants affect biotech cash planning?
Grants can provide funding for eligible research activities and reduce the amount of equity capital required for those activities. However, grant timing, eligibility, reporting requirements, and restrictions should be incorporated into the cash forecast.
What should a biotech company prepare before fundraising?
A company should typically maintain an updated financial model, accurate financial statements, clean cap-table records, organized supporting documents, realistic runway projections, and a clear explanation of how new funding will be used to reach specific milestones.
Buying Time for the Science
In biotech, time is often one of the most valuable resources a company has, and cash is what helps buy it. Founders who budget around milestones, forecast honestly, control their largest costs, and pursue non-dilutive funding can create more financial flexibility between funding rounds.
With an experienced finance partner such as K-38 Consulting supporting the numbers, biotech teams can maintain better visibility into runway, align spending with scientific milestones, and prepare more deliberately for the next stage of financing.